Enovix (ENVX) to Release Quarterly Earnings on Thursday

Enovix (NASDAQ:ENVX) is expected to be releasing its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to post earnings of ($0.14) per share and revenue of $8.4320 million for the quarter. Enovix has set its Q2 2026 guidance at -0.170–0.130 EPS. Investors can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 5:00 PM ET.

Enovix (NASDAQ:ENVX) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. Enovix had a negative return on equity of 64.28% and a negative net margin of 499.64%.The business had revenue of $7.60 million during the quarter, compared to analyst estimates of $6.95 million. During the same period in the prior year, the company earned ($0.15) earnings per share. Enovix’s revenue was up 49.1% compared to the same quarter last year. On average, analysts expect Enovix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Enovix Price Performance

Shares of NASDAQ ENVX opened at $4.68 on Thursday. The company has a current ratio of 10.97, a quick ratio of 10.65 and a debt-to-equity ratio of 2.14. The stock has a fifty day simple moving average of $6.29 and a two-hundred day simple moving average of $6.29. Enovix has a 1-year low of $4.53 and a 1-year high of $15.40. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of -5.64 and a beta of 2.26.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ENVX shares. Craig Hallum dropped their price target on Enovix from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, May 14th. JPMorgan Chase & Co. lowered Enovix from a “neutral” rating to an “underweight” rating in a report on Wednesday, May 6th. Benchmark decreased their price objective on Enovix from $25.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, May 14th. Oppenheimer lowered their price objective on Enovix from $24.00 to $21.00 and set an “outperform” rating on the stock in a research note on Thursday, May 14th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Enovix in a report on Thursday, May 14th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $12.64.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ENVX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Enovix by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 98,318 shares of the company’s stock worth $722,000 after acquiring an additional 4,780 shares in the last quarter. NewEdge Advisors LLC grew its position in shares of Enovix by 10.4% in the first quarter. NewEdge Advisors LLC now owns 26,257 shares of the company’s stock valued at $193,000 after purchasing an additional 2,481 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Enovix by 65.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,137,777 shares of the company’s stock valued at $8,351,000 after purchasing an additional 449,934 shares in the last quarter. Caxton Associates LLP purchased a new position in shares of Enovix in the first quarter valued at $190,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Enovix by 18.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 358,023 shares of the company’s stock valued at $2,628,000 after purchasing an additional 55,676 shares during the period. 50.92% of the stock is currently owned by hedge funds and other institutional investors.

About Enovix

Enovix Corporation (NASDAQ: ENVX) develops and manufactures advanced lithium-ion battery cells with a patented three-dimensional silicon-anode architecture. The company’s core focus is on delivering high energy density, improved safety, and longer cycle life compared to conventional graphite-based cells. Enovix’s technology targets a range of applications, including consumer electronics, wearable devices, electric vehicles and stationary energy storage systems.

Founded in 2011 and headquartered in Fremont, California, Enovix has built pilot production capability and is scaling up manufacturing capacity to meet growing demand.